Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/15/22 → 1/29/24 |
Funding
- Janssen Research and Development LLC: $27,139.00
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and D
- Monohan, Gregory (PI)